Here is a formal academic-style abstract inspired by the given summary and keywords:

This study examines the updated NCCN Guidelines Insights for Breast Cancer Version 4.2021, focusing on adjuvant systemic therapy recommendations for early-stage, hormone receptor-positive, HER2-negative breast cancer. The revised guidelines provide evidence-based updates on optimal treatment strategies, reflecting recent advances in the field. The implications of these changes for clinical practice and patient outcomes are discussed, highlighting the evolving landscape of breast cancer management in 2021.